Duy-Khiet Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Duy-Khiet Ho has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Cuong Hung Luu
School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia
2 shared publications - Doo Sung Lee
School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Gyeonggi-do, Republic of Korea
2 shared publications - Jaeyun Kim
School of Chemical Engineering Sungkyunkwan University (SKKU) Suwon Republic of Korea
2 shared publications - Mohanapriya Murugesan
Graduate School of Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, Gyeonggi-do, Republic of Korea
2 shared publications - Panchanathan Manivasagan
Department of Chemistry and Bio Science, Kumoh National Institute of Technology, Daehak-ro 61, Gumi-si 39177, Gyeongsangbuk-do, Republic of Korea
2 shared publications - Thanh Loc Nguyen
School of Chemical Engineering
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1312
Correction: Phan et al. Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics 2022, 14, 709
- 16 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1312
Open AccessCorrection: Phan et al. Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics 2022, 14, 709
- Open Access
- 26 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 709
Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment
Despite the potential of hydrogel-based localized cancer therapies, their efficacy can be limited by cancer recurrence. Therefore, it is of great significance to develop a hydrogel system that can provoke robust and durable immune response in the human body. This study has developed an injectable protein-polymer-based porous hydrogel network composed of lysozyme and poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide (PCLA) (Lys-PCLA) bioconjugate for the active recruitment dendritic cells (DCs). The Lys-PCLA bioconjugates are prepared using thiol-ene reaction between thiolated lysozyme (Lys-SH) and acrylated PCLA (PCLA-Ac). The free-flowing Lys-PCLA bioconjugate sols at low temperature transformed to immovable gel at the physiological condition and exhibited stability upon dilution with buffers. According to the in vitro toxicity test, the Lys-PCLA bioconjugate and PCLA copolymer were non-toxic to RAW 263.7 cells at higher concentrations (1000 µg/mL). In addition, subcutaneous administration of Lys-PCLA bioconjugate sols formed stable hydrogel depot instantly, which suggested the in situ gel forming ability of the bioconjugate. Moreover, the Lys-PCLA bioconjugate hydrogel depot formed at the interface between subcutaneous tissue and dermis layers allowed the active migration and recruitment of DCs. As suggested by these results, the in-situ forming injectable Lys-PCLA bioconjugate hydrogel depot may serve as an implantable immune niche for the recruitment and modification of DCs.
- 26 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 709
Open AccessInjectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment
Despite the potential of hydrogel-based localized cancer therapies, their efficacy can be limited by cancer recurrence. Therefore, it is of great significance to develop a hydrogel system that can provoke robust and durable immune response in the human body. This study has developed an injectable protein-polymer-based porous hydrogel network composed of lysozyme and poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide (PCLA) (Lys-PCLA) bioconjugate for the active recruitment dendritic cells (DCs). The Lys-PCLA bioconjugates are prepared using thiol-ene reaction between thiolated lysozyme (Lys-SH) and acrylated PCLA (PCLA-Ac). The free-flowing Lys-PCLA bioconjugate sols at low temperature transformed to immovable gel at the physiological condition and exhibited stability upon dilution with buffers. According to the in vitro toxicity test, the Lys-PCLA bioconjugate and PCLA copolymer were non-toxic to RAW 263.7 cells at higher concentrations (1000 µg/mL). In addition, subcutaneous administration of Lys-PCLA bioconjugate sols formed stable hydrogel depot instantly, which suggested the in situ gel forming ability of the bioconjugate. Moreover, the Lys-PCLA bioconjugate hydrogel depot formed at the interface between subcutaneous tissue and dermis layers allowed the active migration and recruitment of DCs. As suggested by these results, the in-situ forming injectable Lys-PCLA bioconjugate hydrogel depot may serve as an implantable immune niche for the recruitment and modification of DCs.